- The 90-day interim topline efficacy readout from Mercury 1, the first Phase 3 clinical trial for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, is expected in September 2016.
Catalyst
Slingshot members are tracking this event:
Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%; Trial On Track for Topline 90-day Efficacy Readout in September 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AERI |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2016
Occurred Source:
http://investors.aeriepharma.com/releasedetail.cfm?ReleaseID=989137
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Complete Enrollment, Mercury 1 Phase 3 Trial, Roclatan, Netarsudil, Latanoprost Ophthalmic Solution
